Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Juan Martin-Liberal

Showing results (1-10 of 59) with videos related to

Pageof 6
Sort By:
Intractable & Rare Diseases Research|October 25, 2014
Leiomyosarcoma: Principles of managementJuan Martin-Liberal
The Lancet. Oncology|September 17, 2018
Encorafenib plus binimetinib: an embarrassment of richesJuan Martin-Liberal
Expert Opinion on Drug Safety|August 14, 2013
Safety evaluation of trabectedin in treatment of soft-tissue sarcomasJuan Martin-Liberal, Ian Judson
Future Oncology (London, England)|February 17, 2015
Vemurafenib for the treatment of BRAF mutant metastatic melanomaJuan Martin-Liberal, James Larkin
Expert Opinion on Pharmacotherapy|April 29, 2014
New RAF kinase inhibitors in cancer therapyJuan Martin-Liberal, James Larkin
Expert Opinion on Drug Safety|May 1, 2015
Safety of pembrolizumab for the treatment of melanomaJuan Martin-Liberal, Tiana Kordbacheh, James Larkin
Expert Review of Anticancer Therapy|August 16, 2013
Antiangiogenic approach in soft-tissue sarcomasJuan Martin-Liberal, Ian Judson, Charlotte Benson
Expert Opinion on Pharmacotherapy|November 26, 2013
New drugs in sarcomasJuan Martin-Liberal, Charlotte Benson, Ian Judson
Therapeutics and Clinical Risk Management|December 26, 2014
Trabectedin for advanced soft tissue sarcomas: optimizing useAlison Reid, Juan Martin-Liberal, Charlotte Benson
Cancer Immunology, Immunotherapy : CII|May 20, 2016
Determining predictive factors for immune checkpoint inhibitor toxicity: Response to Letter to the Editors "A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome"Lavinia Spain, James Larkin, Juan Martin-Liberal
Pageof 6

Showing results (1-10 of 59) with videos related to

Sort By:
Pageof 6
Intractable & Rare Diseases Research|October 25, 2014
Leiomyosarcoma: Principles of managementJuan Martin-Liberal
The Lancet. Oncology|September 17, 2018
Encorafenib plus binimetinib: an embarrassment of richesJuan Martin-Liberal
Expert Opinion on Drug Safety|August 14, 2013
Safety evaluation of trabectedin in treatment of soft-tissue sarcomasJuan Martin-Liberal, Ian Judson
Future Oncology (London, England)|February 17, 2015
Vemurafenib for the treatment of BRAF mutant metastatic melanomaJuan Martin-Liberal, James Larkin
Expert Opinion on Pharmacotherapy|April 29, 2014
New RAF kinase inhibitors in cancer therapyJuan Martin-Liberal, James Larkin
Expert Opinion on Drug Safety|May 1, 2015
Safety of pembrolizumab for the treatment of melanomaJuan Martin-Liberal, Tiana Kordbacheh, James Larkin
Expert Review of Anticancer Therapy|August 16, 2013
Antiangiogenic approach in soft-tissue sarcomasJuan Martin-Liberal, Ian Judson, Charlotte Benson
Expert Opinion on Pharmacotherapy|November 26, 2013
New drugs in sarcomasJuan Martin-Liberal, Charlotte Benson, Ian Judson
Therapeutics and Clinical Risk Management|December 26, 2014
Trabectedin for advanced soft tissue sarcomas: optimizing useAlison Reid, Juan Martin-Liberal, Charlotte Benson
Cancer Immunology, Immunotherapy : CII|May 20, 2016
Determining predictive factors for immune checkpoint inhibitor toxicity: Response to Letter to the Editors "A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome"Lavinia Spain, James Larkin, Juan Martin-Liberal
Pageof 6